Velmanase alfa
Velmanase alfa (LAMZEDE) is an enzyme replacement therapy used to treat the physical symptoms of alpha-mannosidosis, a rare inherited storage disease.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Velmanase alfa (Lamzede) is a specialist enzyme replacement therapy for alpha-mannosidosis, a rare inherited storage disease. It supplies the missing enzyme so cells can clear the sugar-containing waste that damages the body, though it does not treat brain-related symptoms. Allergic-type infusion reactions are common, and beyond those people mostly notice cold symptoms, fever, headache or joint pain. The one thing to look for is its boxed warning for severe allergic reactions, including anaphylaxis, which is why every weekly IV (into a vein) dose is given with emergency and CPR equipment ready. Women who could become pregnant need effective birth control during treatment and for 14 days after the last dose.
Clinical pearls
- Your care team may give an antihistamine, fever reducer or steroid before each infusion to help head off reactions.
- Reactions can begin after the infusion ends, so hives, facial swelling or trouble breathing later that day still need emergency care.
- Acute kidney failure has been reported, so tell your doctor promptly about changes in urination or new swelling.
- Before the first infusion, tell the team about any past reaction to other enzyme therapies or biologic medicines.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
LAMZEDE can cause severe allergic reactions, including anaphylaxis — a sudden, life-threatening reaction that can affect breathing and blood pressure. This risk applies to any patient treated with this medicine. Every infusion must take place where emergency equipment (including CPR equipment) is immediately available. Watch for warning signs during or after the infusion, such as hives, swelling, vomiting, a drop in blood pressure, or bluish skin. If a severe reaction happens, the infusion must be stopped at once and emergency medical treatment started immediately.
Patient information guide A plain-language walkthrough of Velmanase alfa, written from its FDA label.
What Velmanase alfa is used for
▾
Velmanase alfa (LAMZEDE) is approved to treat the physical — non-brain-related — symptoms of alpha-mannosidosis in adults and children. This is a rare inherited condition where the body cannot properly break down certain sugar-containing molecules.
- Treatment of non-central nervous system (non-CNS) manifestations of alpha-mannosidosis
- Approved for both adult and pediatric patients
How Velmanase alfa works
▾
Alpha-mannosidosis is caused by a genetic change that leaves the body with little or no working alpha-mannosidase enzyme. This enzyme is responsible for breaking down sugar-containing waste products inside lysosomes — tiny compartments inside cells that act like recycling centers. Without it, waste accumulates and damages tissues throughout the body.
Velmanase alfa supplies a working copy of this missing enzyme. After infusion into the bloodstream, it binds to a receptor on the cell surface called the mannose-6-phosphate receptor, which carries it into the lysosome. Inside the lysosome, it is thought to break down the accumulated waste, reducing its harmful buildup.
Velmanase alfa dosage
▾
Velmanase alfa is given as an intravenous (IV) infusion once every week at a clinic or infusion center — it cannot be taken by mouth. Each infusion lasts at least 60 minutes; the exact rate may be adjusted based on weight or how you are tolerating the infusion.
- Before each infusion, your care team may pre-treat you with antihistamines, fever reducers, or corticosteroids to reduce the chance of a reaction
- If you miss a dose, restart as soon as possible — unless your next scheduled dose is within 3 days, in which case just take the next scheduled dose as planned
- Always follow your care team's specific instructions
Dosing details from the FDA-approved label
From the Velmanase alfa prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
The recommended dosage of LAMZEDE is 1 mg/kg (actual body weight) administered once every week as an intravenous infusion.
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment. ( 2.1 ) Consider pretreating with antihistamines, antipyretics, and/or corticosteroids prior to LAMZEDE administration. ( 2.2 ) Recommended LAMZEDE dosage is 1 mg/kg (actual body weight) administered once every week as an intravenous infusion. ( 2.2 ) See the full prescribing information for dosage modifications due to hypersensitivity reactions or IARs. ( 2.3 ) See the full prescribing information for reconstitution and administration instructions. ( 2.4 , 2.5 ) 2.1 Important Recommendations Prior to LAMZEDE Treatment Initiation For females of reproductive potential, verify that the patient is not pregnant [see Use in Specific Populations ( 8.1 , 8.3 )] . 2.2 Recommended Dosage and Administration Prior to LAMZEDE administration, consider pre-treating with antihistamines, antipyretics, and/or corticosteroids [see Warnings and Precautions ( 5.1 , 5.2 )] . The recommended dosage of LAMZEDE is 1 mg/kg (actual body weight) administered once every week as an intravenous infusion. The total volume of infusion is determined by the patient’s actual body weight and should be administered over a minimum of 60 minutes for patients weighing up to 49 kg. Patients weighing 50 kg and greater should be infused at a maximum infusion rate of 25 mL/hour to control the protein load [ s ee Dosage and Administration ( 2.4 )] . If one or more doses are missed, restart the treatment as soon as possible, as long as it is at least 3 days from the next scheduled dose. If it is within 3 days from the next scheduled dose, give only the next dose per schedule. 2. 3 Dosage and Administration Modifications Due to Hypersensitivity Reactions and/or Infusion-Associated Reactions In the event of a severe hypersensitivity reaction (including anaphylaxis) or severe infusion-associated reaction (IAR), immediately discontinue LAMZEDE administration and initiate appropriate medical treatment. For additional recommendations in the event of a severe hypersensitivity reaction or IAR, see Warnings and Precautions ( 5.1 , 5.2 ).
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Velmanase alfa side effects
▾
The most commonly reported side effects in clinical trials included:
Common side effects
- Nasopharyngitis (common cold symptoms)
- Fever (pyrexia)
- Headache
- Joint pain (arthralgia)
- Hypersensitivity (allergic) reactions
- Tonsillitis
- Eye itching
- Fainting (syncope)
- Gastroenteritis (stomach upset with nausea or diarrhea)
When to get medical help
- Signs of a severe allergic reaction (anaphylaxis): bluish skin color, low blood pressure, vomiting, hives, facial swelling, or tremor — seek emergency care immediately
- Severe infusion reactions: stop the infusion and get medical help right away
- Acute kidney failure has been reported — tell your doctor right away if you notice changes in urination or swelling
More seriously, some patients have experienced anaphylaxis or severe allergic infusion reactions, and one patient developed acute kidney failure. Tell your care team immediately if you feel unwell during or after an infusion.
Velmanase alfa warnings and precautions
▾
- Severe allergic reactions and anaphylaxis: Half of all patients in trials had some form of allergic reaction. Five percent experienced anaphylaxis. Emergency equipment must be available at every infusion. Signs include hives, facial swelling, vomiting, low blood pressure, bluish skin, or tremor.
- Infusion-associated reactions (IARs): Reactions tied to the infusion itself can occur. Mild reactions may be managed by slowing or pausing the infusion; severe reactions require stopping the infusion and emergency treatment.
- Embryo-fetal toxicity: Animal studies showed serious birth defects at exposures relevant to human dosing. Women who could become pregnant must use effective contraception during treatment and for 14 days after stopping.
- Antibody development: Some patients developed anti-drug antibodies (ADA), which were associated with more severe allergic reactions.
Velmanase alfa interactions
▾
The FDA label for velmanase alfa does not identify specific drug, food, or supplement interactions.
- Always tell your full care team about every medication, supplement, and herbal product you take before starting velmanase alfa
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Velmanase alfa
▾
- Pregnancy: This medicine may cause serious harm to an unborn baby. Women who could become pregnant must be confirmed not pregnant before starting and must use effective contraception during treatment and for 14 days after the last dose.
- Previous severe allergic reactions: If you have had anaphylaxis or a severe reaction to velmanase alfa before, discuss with your doctor whether it is safe to continue — a desensitization procedure may be considered.
- Children: Velmanase alfa has been studied in children as young as 3 years old. Dosing is based on body weight; your care team will manage this carefully.
- Anti-drug antibodies: Patients who develop antibodies against this medicine appear to be at higher risk for serious allergic reactions — your care team may monitor for this.
What Velmanase alfa does in the body
▾
In people with alpha-mannosidosis, the blood contains high levels of sugar-containing waste molecules called oligosaccharides. These elevated levels serve as a measurable marker of how active the disease is. In clinical studies, treatment with velmanase alfa led to meaningful reductions in these serum oligosaccharide levels, suggesting the enzyme is successfully breaking down the accumulated waste in the body.
How your body processes Velmanase alfa
▾
Velmanase alfa reaches its peak blood concentration during the weekly IV infusion, then is gradually cleared from the body. Its mean terminal half-life — the time it takes for half the drug to leave the body — is about 33.6 hours in adults. The drug is broken down through normal protein-digesting pathways into small peptides (protein fragments). In children aged 6–17, the drug behaves similarly to adults at the same weight-based dose, though blood levels are somewhat lower than in adults.
How to store Velmanase alfa
▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Velmanase alfa: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Velmanase alfa — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is alpha-mannosidosis, and how does this medicine help?
▾
How is this medicine given, and will I need to go somewhere special for it?
▾
What side effects should I expect, and which ones are a reason to call for help?
▾
I'm a woman of childbearing age. Is there anything I need to know before starting this?
▾
What happens if I miss a weekly dose?
▾
I heard that some people develop antibodies to this medicine. What does that mean for me?
▾
Is Velmanase alfa available over the counter?
▾
When was Velmanase alfa first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Velmanase alfa on HelloPharmacist
Velmanase alfa on the U.S. market: products, makers and brands
How Velmanase alfa appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
The FDA lists Velmanase alfa products; the earliest marketing or approval year on record is 2023. Brand names on the directory include Lamzede; the rest are generics.
How widely Velmanase alfa is used (Medicaid data)
A general measure of how commonly Velmanase alfa is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Velmanase alfa is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Velmanase alfa prescribed? Of the 1,601 medications we measure, Velmanase alfa ranks #1,497 by Medicaid prescriptions — more than 6% of them.
Utilization by Velmanase alfa product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
velmanase alfa-tycv 10 MG Injection
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2630729
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Velmanase alfa, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 4 listed Velmanase alfa NDCs with Medicaid activity.
Velmanase alfa side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Velmanase alfa — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Velmanase alfa in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Velmanase alfa FDA approval history
How Velmanase alfa went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Velmanase alfa recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Velmanase alfa recalls since July 2021.
✅No Velmanase alfa recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2630725 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 2630728No current FDA listingClinical drug / strength (SCD) tycv 10 MGRxCUI 2630729
Look up RxCUI 2630725 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Velmanase alfa supply and shortage status
Whether Velmanase alfa is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Velmanase alfa brand names
Velmanase alfa is sold under one brand name in the FDA directory — Lamzede. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Velmanase alfa drug class (RxNorm)
Velmanase alfa belongs to the Recombinant Human Lysosomal alpha-Mannosidase class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Velmanase alfa page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Chiesi USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →